Astellas submits application for marketing acceptance of enzalutamide for prostate cancer Astellas Pharma Inc. and Medivation, Inc. today announced that Astellas provides submitted a credit card applicatoin for marketing acceptance of enzalutamide to the Ministry of Health, Welfare and Labour in Japan for the treatment of prostate cancer. Enzalutamide is normally a novel, once-daily, oral androgen receptor signaling inhibitor. It inhibits multiple actions in the androgen receptor signaling pathway, which has been shown to decrease cancer cell development and will induce cancer cell loss of life . This filing software is based mainly on results obtained from the global Phase 3 trial and a Phase 1-2 trial carried out in Japan.Their responses were in comparison to assess variations and similarities of opinion relating to clinical, scientific and economic factors. SOURCE Decision Resources.. Antidepressants keep killing ladies, thereby ‘curing’ their depression Proof continues to mount that even supposedly safer antidepressants increase women’s risk of stroke and death. One of the factors that doctors choose selective serotonin reuptake inhibitor antidepressants to the older tricyclics can be that the latter are known to have negative effects on heart function . In the last five years, evidence provides began to emerge that SSRIs may also increase cardiovascular risk, particularly among older women. More strokes, deaths among womenBecause older females are also at elevated threat of cardiovascular disease, a study published in the Archives of Internal Medicine in December 2009 examined whether SSRIs increased this risk among females participating in the Women’s Health Initiative study.